Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort.

被引：0

作者：

Hainsworth, John ^{[1
]}

Friedman, Claire F. ^{[2
]}

Kurzrock, Razelle ^{[3
]}

Spigel, David R. ^{[1
]}

Burris, Howard ^{[1
]}

Sweeney, Christopher J. ^{[4
]}

Meric-Bernstam, Funda ^{[5
]}

Wang, Yong ^{[6
]}

Levy, Jonathan ^{[6
]}

Shames, David ^{[6
]}

Schulze, Katja ^{[6
]}

Patel, Arisha ^{[6
]}

Swanton, Charles ^{[7
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Genentech Inc, San Francisco, CA 94080 USA

[7] Francis Crick Inst, London, England

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB012

引用

页数：2

共 50 条

[1] Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Friedman, Claire F.
Hainsworth, John D.
Kurzrock, Razelle
Spigel, David R.
Burris, Howard A., III
Sweeney, Christopher J.
Meric-Bernstam, Funda
Wang, Yong
Levy, Jonathan
Grindheim, Jessica
Shames, David S.
Schulze, Katja
Patel, Arisha
Swanton, Charles
[J]. CANCER DISCOVERY, 2022, 12 (03) : 654 - 669
[2] Atezolizumab in patients (pts) with tumor mutational burden (TMB)-high tumors from the TAPISTRY trial.
Dziadziuszko, Rafal
Barlesi, Fabrice
Kim, Jeong Eun
Gadgeel, Shirish M.
Krzakowski, Maciej
Jeong, Jae Ho
Daniele, Gennaro
Chen, David
Hu, Youyou
Wilson, Timothy R.
Simmons, Brian P.
Thomas, David Morgan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA2509 - LBA2509
[3] Clinical Validation of Tumor Mutational Burden (TMB) in Solid Tumors by NGS: Impact of Revised TMB-High Threshold
Parimi , Vamsi
Xian, Rena
Lin, Ming-Tseh
Eshleman, James
Gocke, Christopher
Pallavajjala, Aparna
[J]. MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1071 - 1072
[4] Clinical Validation of Tumor Mutational Burden (TMB) in Solid Tumors by NGS: Impact of Revised TMB-High Threshold
Parimi , Vamsi
Xian, Rena
Lin, Ming-Tseh
Eshleman, James
Gocke, Christopher
Pallavajjala, Aparna
[J]. LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1071 - 1072
[5] Clinical usefulness of tumor mutational burden (TMB) assessed by NGS in solid tumors
Kim, H.
Kim, S. T.
[J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S31 - S31
[6] Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors
Kao, Chester
Powers, Eric
Datto, Michael B.
Green, Michelle
Harrison, Michael Roger
Armstrong, Andrew J.
George, Daniel J.
Clarke, Jeffrey Melson
Strickler, John H.
Zhang, Tian
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[7] Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer
Barroso-Sousa, Romualdo
Jain, Esha
Kim, Dewey
Partridge, Ann H.
Cohen, Ofir
Wagle, Nikhil
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] Tumor Mutational Burden Testing in Solid Tumors
Kwon, Regina
Cheng, Heather H.
Pritchard, Colin C.
[J]. JAMA ONCOLOGY, 2023, 9 (12) : 1725 - 1726
[9] FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
Marcus, Leigh
Fashoyin-Aje, Lola A.
Donoghue, Martha
Yuan, Mengdie
Rodriguez, Lisa
Gallagher, Pamela S.
Philip, Reena
Ghosh, Soma
Theoret, Marc R.
Beaver, Julia A.
Pazdur, Richard
Lemery, Steven J.
[J]. CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4685 - 4689
[10] Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Sha, Dan
Jin, Zhaohui
Budczies, Jan
Kluck, Klaus
Stenzinger, Albrecht
Sinicrope, Frank A.
[J]. CANCER DISCOVERY, 2020, 10 (12) : 1808 - 1825

← 1 2 3 4 5 →